MCPI©: A sub-minute Monte Carlo dose calculation engine for prostate implants

AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137

During the past decade, permanent radioactive source implantation of the prostate has become the standard of care for selected prostate cancer patients, and the techniques for implantation have evolved in many different forms. Although most implants use 125I or 103Pd sources, clinical use of 131Cs sources has also recently been introduced. These sources produce different dose distributions and irradiate the tumors at different dose rates. Ultrasound was used originally to guide the planning and implantation of sources in the tumor. More recently, CT and/or MR are used routinely in many clinics for dose evaluation and planning. Several investigators reported that the tumor volumes and target volumes delineated from ultrasound, CT, and MR can vary substantially because of the inherent differences in these imaging modalities. It has also been reported that these volumes depend critically on the time of imaging after the implant. Many clinics, in particular those using intraoperative implantation, perform imaging only on the day of the implant. Because the effects of edema caused by surgical trauma can vary from one patient to another and resolve at different rates, the timing of imaging for dosimetry evaluation can have a profound effect on the dose reported (to have been delivered), i.e., for the same implant (same dose delivered), CT at different timing can yield different doses reported. Also, many different loading patterns and margins around the tumor volumes have been used, and these may lead to variations in the dose delivered. In this report, the current literature on these issues is reviewed, and the impact of these issues on the radiobiological response is estimated. The radiobiological models for the biological equivalent dose (BED) are reviewed. Starting with the BED model for acute single doses, the models for fractionated doses, continuous low-dose-rate irradiation, and both homogeneous and inhomogeneous dose distributions, as well as tumor cure probability models, are reviewed. Based on these developments in literature, the AAPM recommends guidelines for dose prescription from a physics perspective for routine patient treatment, clinical trials, and for treatment planning software developers. The authors continue to follow the current recommendations on using D90 and V100 as the primary quantitles, with more specific guidelines on the use of the imaging modalities and the timing of the imaging. The AAPM recommends that the postimplant evaluation should be performed at the optimum time for specific radionuclides. In addition, they encourage the use of a radiobiological model with a specific set of parameters to facilitate relative comparisons of treatment plans reported by different institutions using different loading patterns or radionuclides.

Estimation of gamma- and X-ray photons buildup factor in soft tissue with Monte Carlo method

Buildup factor of gamma- and X-ray photons in the energy range 0.2-2MeV in water and soft tissue is computed using Monte Carlo method. The results are compared with the existing buildup factor data of pure water. The difference between soft tissue and water buildup factor is studied. Soft tissue is assumed to have a composition as H(63)C(6)O(28)N. The importance of such work arises from the fact that in medical applications of X- and gamma-ray, soft tissue is usually approximated by water. It is shown that the difference between water and soft tissue buildup factor is usually more than 10%. On the other hand, buildup factor in water resulted from Monte Carlo method is compared with the experimental data appearing in references. It seems there is around 10% error in the reference data as well.

Clinical practice and quality assurance challenges in modern brachytherapy sources and dosimetry

Modern brachytherapy has led to effective treatments through the establishment of broadly applicable dosimetric thresholds for maximizing survival with minimal morbidity. Proper implementation of recent dosimetric consensus statements and quality assurance procedures is necessary to maintain the established level of safety and efficacy. This review classifies issues as either "systematic" or "stochastic" in terms of their impact on large groups or individual patients, respectively. Systematic changes affecting large numbers of patients occur infrequently and include changes in source dosimetric parameters, prescribing practice, dose calculation formalism, and improvements in calculation algorithms. The physicist must be aware of how incipient changes accord with previous experience. Stochastic issues involve procedures that are applied to each patient individually. Although ample guidance for quality assurance of brachytherapy sources exists, some ambiguities remain. The latest American Association of Physicists in Medicine guidance clarifies what is meant by independent assay, changes source sampling recommendations, particularly for sources in sterile strands and sterile preassembled needles, and modifies action level thresholds. The changing environment of brachytherapy has not changed the fact that the prime responsibility for quality assurance in brachytherapy lies with the institutional medical physicist.

Brachytherapy scatter dose calculation in heterogeneous media: I. A microbeam ray-tracing method for the single-scatter contribution

In this work, we propose a framework for calculating brachytherapy dose distributions in heterogeneous media. The approach taken includes analytical calculation of the primary dose, and separately treats contributions of the once-scatter photons and multiple-scatter photons to the total scatter dose. This paper focuses on the evaluation of the once-scatter dose, which is based on a micro-beam ray-tracing model developed by the authors that incorporates an accurate description of the physical scattering of photons (Compton and Rayleigh scattering) with considerable flexibility in accommodating diverse geometries in a heterogeneous medium. The accuracy of the ray-tracing model has been verified by comparing model-calculated once-scatter doses with corresponding Monte Carlo results. For a 22 keV, 27 keV and 300 keV point source in water containing a disc-shaped heterogeneity of whitlockite, stainless steel or lead, our calculated results for once-scatter doses are in excellent agreement with corresponding Monte Carlo results over a wide range of heterogeneity dimensions and positions. Our investigation also explores the differences between physical scattering and isotropic scattering in evaluating the once-scatter dose, and thus enables the domain of applicability of the latter to be assessed. An appropriate method for evaluating the multiple-scatter dose, which together with the micro-beam method described here provides a means to calculate the total dose, is the subject of a companion paper.

Postimplant Dosimetry Using a Monte Carlo Dose Calculation Engine: A New Clinical Standard

PURPOSE

To use the Monte Carlo (MC) method as a dose calculation engine for postimplant dosimetry. To compare the results with clinically approved data for a sample of 28 patients. Two effects not taken into account by the clinical calculation, interseed attenuation and tissue composition, are being specifically investigated.

METHODS AND MATERIALS

An automated MC program was developed. The dose distributions were calculated for the target volume and organs at risk (OAR) for 28 patients. Additional MC techniques were developed to focus specifically on the interseed attenuation and tissue effects.

RESULTS

For the clinical target volume (CTV) D(90) parameter, the mean difference between the clinical technique and the complete MC method is 10.7 Gy, with cases reaching up to 17 Gy. For all cases, the clinical technique overestimates the deposited dose in the CTV. This overestimation is mainly from a combination of two effects: the interseed attenuation (average, 6.8 Gy) and tissue composition (average, 4.1 Gy). The deposited dose in the OARs is also overestimated in the clinical calculation.

CONCLUSIONS

The clinical technique systematically overestimates the deposited dose in the prostate and in the OARs. To reduce this systematic inaccuracy, the MC method should be considered in establishing a new standard for clinical postimplant dosimetry and dose-outcome studies in a near future.

Dosimetric characterization of a novel intracavitary mold applicator for Ir192 high dose rate endorectal brachytherapy treatment

The dosimetric properties of a novel intracavitary mold applicator for 192Ir high dose rate (HDR) endorectal cancer treatment have been investigated using Monte Carlo (MC) simulations and experimental methods. The 28 cm long applicator has a flexible structure made of silicone rubber for easy passage into cavities with deep-seated tumors. It consists of eight source catheters arranged around a central cavity for shielding insertion, and is compatible for use with an endocavitary balloon. A phase space model of the HDR source has been validated for dose calculations using the GEANT4 MC code. GAFCHROMIC EBT model film was used to measure dose distributions in water around shielded and unshielded applicators with two loading configurations, and to quantify the shielding effect of a balloon injected with an iodine solution (300 mg I/mL). The film calibration procedure was performed in water using an 192Ir HDR source. Ionization chamber measurements in a Lucite phantom show that placing a tungsten rod in the applicator attenuates the dose in the shielded region by up to 85%. Inserting the shielded applicator into a water-filled balloon pushes the neighboring tissues away from the radiation source, and the resulting geometric displacement reduces the dose by up to 53%; another 8% dose reduction can be achieved when the balloon is injected with an iodine solution. All experimental results agree with the GEANT4 calculations within measurement uncertainties.

Brachytherapy technology and physics practice since 1950: a half-century of progress

The 50-year tenure of Physics in Medicine and Biology has coincided with some of the most important developments in radiological science, including the introduction of artificial radioactivity, computers and 3D imaging into medicine. These events have profoundly influenced the development of brachytherapy. Although it is not the dominant radiotherapy modality, it continues to play an important role in cancer therapy, more than a century after its introduction. This paper reviews the impact of three broad categories of innovation introduced since 1950 from the North American perspective: the introduction of artificial radioactivity, computer- and image-based treatment planning, and basic single-source dosimetry.

Approaches to calculating AAPM TG-43 brachytherapy dosimetry parameters for Cs137, I125, Ir192, Pd103, and Yb169 sources

Underlying characteristics in brachytherapy dosimetry parameters for medical radionuclides 137Cs, 125I, 192Ir, 103Pd, and 169Yb were examined using Monte Carlo methods. Sources were modeled as unencapsulated point or line sources in liquid water to negate variations due to materials and construction. Importance of phantom size, mode of radiation transport physics--i.e., photon transport only or coupled photon:electron transport, phantom material, volume averaging, and Monte Carlo tally type were studied. For noninfinite media, g(r) was found to degrade as r approached R, the phantom radius. MCNP5 results were in agreement with those published using GEANT4. Brachytherapy dosimetry parameters calculated using coupled photon:electron radiation transport simulations did not differ significantly from those using photon transport only. Dose distributions from low-energy photon-emitting radionuclides 125I and 103Pd were sensitive to phantom material by upto a factor of 1.4 and 2.0, respectively, between tissue-equivalent materials and water at r =9 cm. In comparison, high-energy photons from 137Cs, 192Ir, and 169Yb demonstrated +/- 5% differences in dose distributions between water and tissue substitutes at r=20 cm. Similarly, volume-averaging effects were found to be more significant for low-energy radionuclides. When modeling line sources with L < or = 0.5 cm, the two-dimensional anisotropy function was largely within +/- 0.5% of unity for 137Cs, 125I, and 192Ir. However, an energy and geometry effect was noted for 103Pd and 169Yb, with Pd-103F(0.5,0 degrees)=l.05 and yb-169F(0.5,0 degrees)=0.98 for L=0.5 cm. Simulations of monoenergetic photons for L=0.5 cm produced energy-dependent variations in F(r, theta) having a maximum value at 10 keV, minimum at 50 keV, and approximately 1.0 for higher-energy photons up to 750 keV. Both the F6 cell heating and *F4 track-length estimators were employed to determine brachytherapy dosimetry parameters. F6 was found to be necessary for g(r), while both tallies provided equivalent results for F(r, theta).